Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Other Non-Current Liabilities (2017 - 2022)

Historic Other Non-Current Liabilities for Iterum Therapeutics (ITRM) over the last 6 years, with Q3 2022 value amounting to $1.3 million.

  • Iterum Therapeutics' Other Non-Current Liabilities fell 6446.78% to $1.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.3 million, marking a year-over-year decrease of 6446.78%. This contributed to the annual value of $3.4 million for FY2021, which is 4077.9% down from last year.
  • Per Iterum Therapeutics' latest filing, its Other Non-Current Liabilities stood at $1.3 million for Q3 2022, which was down 6446.78% from $1.7 million recorded in Q2 2022.
  • Iterum Therapeutics' Other Non-Current Liabilities' 5-year high stood at $7.7 million during Q1 2019, with a 5-year trough of $145000.0 in Q2 2018.
  • Its 5-year average for Other Non-Current Liabilities is $4.5 million, with a median of $4.4 million in 2021.
  • Per our database at Business Quant, Iterum Therapeutics' Other Non-Current Liabilities skyrocketed by 520551.72% in 2019 and then tumbled by 6446.78% in 2022.
  • Quarter analysis of 5 years shows Iterum Therapeutics' Other Non-Current Liabilities stood at $951000.0 in 2018, then skyrocketed by 675.81% to $7.4 million in 2019, then decreased by 21.36% to $5.8 million in 2020, then tumbled by 40.78% to $3.4 million in 2021, then tumbled by 62.69% to $1.3 million in 2022.
  • Its Other Non-Current Liabilities was $1.3 million in Q3 2022, compared to $1.7 million in Q2 2022 and $3.2 million in Q1 2022.